Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Grünes Licht vom Kartellamt: Rheinmetall und OHB bauen Bundeswehr-Satellitennetz (Heise) +++ OHB Aktie +4,20%

IMMUTEP Aktie

 >IMMUTEP Aktienkurs 
0.045 EUR    +0.0%    (TradegateBSX)
Ask: 0.045 EUR / 10000 Stück
Bid: 0.043 EUR / 25000 Stück
Tagesumsatz: 247576 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IMMUTEP Aktie über LYNX handeln
>IMMUTEP Performance
1 Woche: +83,3%
1 Monat: +28,6%
3 Monate: -80,4%
6 Monate: -71,1%
1 Jahr: -61,2%
laufendes Jahr: -78,8%
>IMMUTEP Aktie
Name:  IMMUTEP LTD
Land:  Australien
Sektor:  Gesundheit
ISIN/ Wkn:  AU000000IMM6 / A2H81H
Symbol/ Ticker:  YP1B (Frankfurt)
Kürzel:  FRA:YP1B, ETR:YP1B, YP1B:GR
Index:  -
Webseite:  https://www.immutep.com/
Profil:  Immutep Limited is a late-stage biotechnology company specializing in the development of innovative immunotherapies for cancer and autoimmune diseases. Headquartered in Sydney, Australia, with operations spanning Europe and the United States, Immutep..
>Volltext..
Marktkapitalisierung:  31.9 Mio. EUR
Unternehmenswert:  -23.54 Mio. EUR
Umsatz:  2.31 Mio. EUR
EBITDA:  -48.78 Mio. EUR
Nettogewinn:  -47.47 Mio. EUR
Gewinn je Aktie:  -0.03 EUR
Schulden:  0.68 Mio. EUR
Liquide Mittel:  41.15 Mio. EUR
Operativer Cashflow:  -35.16 Mio. EUR
Bargeldquote:  2.11
Umsatzwachstum:  -
Gewinnwachstum:  -81.86%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  IMMUTEP
Letzte Datenerhebung:  17.04.26
>IMMUTEP Kennzahlen
Aktien/ Unternehmen:
Aktien: 1473.72 Mio. St.
Frei handelbar: 97.08%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Neutral
Kursziel: 922.83%
Bewertung:
KGV: -
KGV lG: -
KUV: 26.33
KBV: 0.94
PEG-Ratio: -0.02
EV/EBITDA: -
Rentabilität:
Bruttomarge: 45.35%
Gewinnmarge: -2056.63%
Operative Marge: -2168.05%
Managementeffizenz:
Gesamtkaprendite: -50.93%
Eigenkaprendite: -61.85%
>IMMUTEP Peer Group
Gesundheit, Antikörper- Behandlung, Lungenerkrankungen & -behandlung/ Asthma, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung
 
17.04.26 - 08:30
ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep (SMH)
 
The Bulls N' Bears ASX Runner of the Week is… Bison Resources, which exploded on debut, as punters piled into its prime Nevada gold-silver projects amid ongoing fuel security chaos....
15.04.26 - 14:03
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma (GlobeNewswire EN)
 
SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (“efti”) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need....
15.04.26 - 07:45
Australia′s Immutep rallies over 100% on FDA orphan drug designation (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
15.04.26 - 06:12
Why this ASX biotech stock just rocketed 89% today (Fool)
 
Immutep shares rocket after a fresh FDA win The post Why this ASX biotech stock just rocketed 89% today appeared first on The Motley Fool Australia....
15.04.26 - 04:12
Immutep Granted FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma (Small Caps)
 
Immutep wins FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, boosting exclusivity and regulatory support as TACTI-004 winds down....
14.04.26 - 20:27
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP (PR Newswire)
 
NEW YORK, April 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading......
10.04.26 - 00:03
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP (PR Newswire)
 
NEW YORK, April 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading......
04.04.26 - 18:09
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP (PR Newswire)
 
NEW YORK, April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep Ltd. may have issued materially misleading......
02.04.26 - 16:07
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP (PR Newswire)
 
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......
24.03.26 - 06:12
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP (PR Newswire)
 
NEW YORK, March 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially......
20.03.26 - 07:30
ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia (SMH)
 
The Bulls N' Bears ASX Runner of the Week is… Immutep. The oncology mid-cap bounced hard from last week's 90 per cent drop, gaining 53 per cent after a brutal sell-off....
20.03.26 - 02:30
HotList stocks: Northern Star, Immutep, Lodestar, and other trending companies in Week 12 (Market Herald)
 
Good afternoon, and welcome to the HotCopper HotList column. Every week, ASX…...
19.03.26 - 04:30
Thursday’s HotCopper trends: Racura, EVR, Immutep, and other daily topics | March 19 (Market Herald)
 
Racura is well out in front on the Australian bourse topic-wise today…...
18.03.26 - 22:31
IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky (PR Newswire)
 
Immutep Reported TACTI-004 Futility Analysis Was "On Track" in January 2026 -- Weeks Later the Trial Was Halted After Failing to Meet Efficacy Endpoints NEW YORK, March 18, 2026 /PRNewswire/ -- Shareholders of Immutep Ltd. (NASDAQ: IMMP) who lost money are urged to act now. On January 30,......
18.03.26 - 20:03
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP (PR Newswire)
 
NEW YORK, March 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially......
13.03.26 - 13:18
Immutep-Aktie stürzt nach Abbruch von Lungenkrebsstudie um 80 % ab (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
13.03.26 - 12:00
Immutep halts late-stage trial for lead asset after efficacy analysis (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.03.26 - 08:25
XFRA: YP1B: Wiederaufnahme/Resumption (XETRA)
 
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN IMMUTEP LTD YP1B AU000000IMM6 AB/FROM ONWARDS 13.03.2026...
13.03.26 - 05:00
HotCopper Highlights Week 11: Immutep scalped; Syrah Trump’s latest victim; Japan’s Lynas handout & more (Market Herald)
 
Good Afternoon, I'm Jon Davidson, it's a Friday and you know what…...
13.03.26 - 04:00
The ides of March come for Immutep as lung cancer trial cancellation triggers plummet (Market Herald)
 
Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after…...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Illusionen sind eine Sache, die ein Mann gleichzeitig mit seinen Haaren und Zähnen verliert. - Franziska Friedl
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!